The Federal Health Service Surveillance Service, known as Roszdravnadzor, has blocked 1,181 websites that offered drugs for medical abortion. This action reflects a sustained effort by regulatory authorities to curb the online sale of abortion-related medications and to tighten oversight over how such drugs are marketed and distributed. The move follows coordinated monitoring by the department and indicates a continuing push to remove unregulated or unsafe sources from the market while ensuring that legitimate medical channels remain compliant with national standards.
Roszdravnadzor stated that ongoing studies will continue, but the outcome is not expected to reduce the overall availability of abortion medications within the country. In practical terms, this means continued enforcement against illegal vendors while preserving access through approved medical suppliers and pharmacies. The agency emphasizes that the core goal is to maintain safe, regulated access to necessary medicines without creating unnecessary barriers for patients seeking legitimate medical care.
In coverage of the situation, the publication noted that prescribing these medications does not present significant difficulties for doctors within the regulated system. This underscores that medical professionals operating under established guidelines can continue to manage abortion-related care while staying within legal and clinical protocols. The focus remains on patient safety, proper dosing, and appropriate clinical supervision rather than on punitive measures for clinicians who follow approved practices.
Earlier, the Ministry of Health of the Russian Federation introduced a bill to place drugs used for abortion under a regime of subject-quantitative accounting and tighter control over their circulation. Such a move would require closer tracking of quantities, distribution channels, and inventory levels to prevent misuse and to ensure that only authorized quantities are dispensed through licensed providers. This legislative step reflects a broader strategy to align abortion-related medications with higher standards of regulatory oversight and accountability.
Responding to these developments, the head of the Ministry of Health, Mikhail Murashko, stated that the department intends to strengthen medication control for medical abortions. Strengthened oversight is expected to enhance patient safety by ensuring appropriate prescribing practices, monitoring supply chains, and reducing risks associated with improper handling or diversion of medications. This regulatory posture signals a careful balance between access to essential medical services and the protection of public health interests.
In related discussions, Murashko had previously proposed compensation measures related to the welfare of children. The idea underscored a broader public policy concern that informs the health strategy, aiming to address social and economic considerations connected with reproductive choices. While specifics were not detailed in the initial discourse, the proposal highlights the government’s willingness to integrate health policy with social support mechanisms, reflecting an approach that considers broader outcomes for families and communities.